RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma

This real-world study is collecting data on how well a drug called tunlametinib works in people with advanced melanoma (a type of skin cancer) that has a specific genetic change called an NRAS mutation. Unlike a controlled clinical trial, this is a registry study observing patients receiving this treatment as part of their regular cancer care. **You may be eligible if:** - You are 18 years of age or older - You have been diagnosed with locally advanced or metastatic melanoma, confirmed by lab testing - Your tumor has tested positive for an NRAS mutation - You have already received and not responded to immunotherapy (anti-PD-1/PD-L1 drugs) - You are able to take oral medications **You may NOT be eligible if:** - You are currently enrolled in another clinical drug trial - You are pregnant or breastfeeding - Your doctors have decided that targeted therapy is not appropriate for you - There are other personal or social factors that make participation unsafe or impractical Talk to your doctor to see if this trial is right for you.